Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 6, 2008, Pages 498-503

  Irani, S ^b   Krevsky, B ^b   Desipio, J ^b   Kim Jaffe, J ^b   Maqbool, S ^b   Fisher, R S ^a,b  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN EXPERIMENT; LANZA SCORE; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STOMACH ANTRUM; STOMACH MUCOSA LESION; STOMACH PARAMETERS; STOMACH PROTECTION; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ASPIRIN; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTRIC MUCOSA; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROTON PUMPS; TIME FACTORS;

EID: 39749121689     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03600.x     Document Type: Article

References (19)

1. O'Laughlin JC, Silvoso GR, Ivey KJ. Healing of aspirin-associated peptic ulcer disease despite continued salicylic ingestion. Arch Int Med 1981 141: 781 3.
2. Yeomans ND, Tulassay Z, Juhasz L, et al. The acid suppression trial: ranitidine versus omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Eng J Med 1998 338: 719 26.
3. Hawkey CJ, Karrasch JA, Szczepanski L, et al. The Omeprazole versus Misopristol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998 338: 727 34.
4. Simonian HP, Vo L, Doma S, Fisher RS, Parkman HP. Regional postprandial differences in pH within the stomach and gastroesophageal junction after meals of different composition. Dig Dis Sci 2005 50: 2276 85.
5. Vo L, Simonian H, Doma S, Fisher RS, Parkman HP. Effects of rabeprazole on regional gastric acidity and the postprandial acid layer in normal subjects. A randomized, double-blind, placebo-controlled study. J Aliment Pharm Ther 2005 21: 1321 30.
6. Vo L, Simonian HP, Doma S, Fisher RS, Parkman HP. First day effects of rabeprazole on nocturnal regional intragastric pH. Am J Gastroenterol 2004 97 (Suppl. 10 S16.
7. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-hour intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998 12: 1079 89.
8. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003 17: 1507 14.
9. Lanza F. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin and other nonsteroidal anti-inflammatory agents. Am J Med 1984 77: 19 24.
10. Graham DY, Smith JL, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci 1983 28: 1 6.
11. Laughlin JC, Hoftiezes JW, Ivey KT. Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours and 2 weeks after administration. Scand J Gastroenterol 1981 16 (Suppl. 67 211 4.
12. Lanza F, Royer GL Jr., Nelson RS, Rack MF, Seckman CC. Ethanol, aspirin, ibuprofen and the gastroduodenal mucosa: an endoscopic assessment. Am J Gastroenterol 1985 80: 767 9.
13. Miner P Jr., Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 98: 2616 20.
14. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004 60: 531 9.
15. Goldstein JL, Miner PB Jr., Schlesinger PK, Liu S, Silberg SG. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2006 23: 1189 96.
16. Laheij RJ, Van Rossum LG, Jansen JB, Verheugt FW. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther 2003 18: 109 15.
17. Miner P Jr., Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002 97: 1332 9.
18. Pantoflickova D, Dorta G, Jornod P, et al. Identification of the characteristics influencing the onset and degree of antisecretory activity of PPIs. Gastroenterology 2000 118: A1290 (abstract).
19. Jaworski T, Sarosiek I, Sostarich S, et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci 2005 50: 357 65.